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Background: Adult cancer survivors often experience substantial psychological
morbidity following the completion of acute cancer treatment. Unfortunately, current
psychological interventions are of limited efficacy. This study explored if metacognitive
therapy (MCT); a brief transdiagnostic psychological intervention was potentially
efficacious and could be delivered effectively to adult cancer survivors with psychological
morbidity.
Methods: An open trial with 3- and 6-month follow-up evaluated the treatment
effects of MCT in 27 consecutively referred individuals to a clinical psychology health
service specializing in psycho-oncology. Each participant received a maximum of six
1-hour sessions of MCT. Levels of anxiety, depression, fear of cancer recurrence,
post-traumatic stress symptoms, health related quality of life, and metacognitive beliefs
and processes were assessed using self-report questionnaires.
Results: MCT was associated with statistically significant reductions across all outcome
measures which were maintained through to 6-month follow-up. In the ITT sample
on the primary treatment outcome measure, the Hospital Anxiety and Depression
Scale-Total, 59% of participants met recovery criteria at post-treatment and 52%
at 6-month follow-up, respectively. No participants significantly deteriorated. In the
completer sample (N = 20), 80% recovered at post-treatment and 70% at 6-month
follow-up. MCT was acceptable to patients with approximately 75% of patients
completing all treatment sessions.
Conclusion: MCT, a brief transdiagnostic psychological intervention can be delivered
effectively to a heterogenous group of cancer survivors with promising treatment effects.
Examining the efficacy of brief MCT against the current gold standard psychological
intervention would be a valuable advance toward improving the quality of life of cancer
survivors.
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INTRODUCTION
The incidence of cancer in the United Kingdom is projected to
increase by 2% over the next 15 years with survival rates also
increasing. It is estimated that survival rates have doubled over
the past 40 years with a ten-year survival rate of approximately
50% (Cancer Research UK, 2017) in 2016, there were an
estimated 15.5 million cancer survivors which is expected to
increase to 20.3 million by 2026 (National Cancer Institute,
2018). Psychological morbidity is common in cancer survivors.
Approximately 25% of cancer survivors have clinically significant
levels of anxiety and depression that could benefit from treatment
(Hoffman et al., 2009). Posttraumatic stress disorder symptoms
are common in cancer survivors with estimates ranging from
6 to 45% (Swartzman et al., 2017). Fear of cancer recurrence
(FCR) is highly prevalent, a systematic review concluded that
almost 60% of cancer survivors experience debilitating FCR
(Simard and Savard, 2015). Psychological morbidity adversely
impacts ongoing cancer care by reducing attendance at follow
up screening appointments (DiMatteo et al., 2000; Thewes et al.,
2014), health related quality of life (LeMasters et al., 2013) and
increases healthcare costs (Carlson and Bultz, 2004; Jansen et al.,
2016) and use of healthcare services (Elliott et al., 2011).
The substantial prevalence and associated problems with
psychological morbidity in cancer survivors requires effective
interventions. Unfortunately, highly efficacious psychological
interventions are unavailable (Rehse and Pukrop, 2003; Osborn
et al., 2006; Faller et al., 2013). The most widely evaluated and
recommended psychological intervention is cognitive behavioral
therapy (CBT) but it may be that core components of
CBT; labeling cognitive distortions and reality testing negative
automatic thoughts (NATs) are clinically limited where NATs will
frequently reflect accurate thoughts about cancer recurrence and
morbidity (Greer et al., 2010; Cook et al., 2015b). An intervention
which does not need to focus on the content of cognition
i.e., NATs, but instead focuses on core psychological processes
underpinning psychological morbidity may be more efficacious
for cancer survivors.
Metacognitive therapy (MCT; Wells, 2009) offers an
alternative psychological approach to the treatment of
psychological morbidity in cancer survivors. MCT is
derived from a trans-diagnostic theory of psychopathology,
the Self-Regulatory Executive Function (S-REF) model
(Wells and Matthews, 1994, 1996). The model states that
psychological morbidity becomes persistent when people use the
cognitive-attentional syndrome (CAS) in response to unwanted
thoughts. The CAS has three broad main components; (i)
perseveration (worry, rumination, over-analyzing, repeatedly
questioning one’s thoughts); (ii) attentional strategies (a
heightened focus on possible signs of threat which can be
internal e.g., signs of anxiety or external e.g., reminders of
cancer); and (iii) unhelpful coping strategies (e.g., searching the
internet for positive outcomes by cancer survivors, avoidance of
reminders of cancer).
The S-REF model states that perseveration is guided by
positive metacognitive beliefs about the helpfulness of worry
and rumination: e.g., “worry will help me be better prepared,”
“worry will ensure that I complete my daily tasks.” Unfortunately,
worry and rumination achieve the opposite, because the person
experiences more negative thoughts and views more situations
as potentially dangerous. The individual repeatedly acts as if
unwanted negative thoughts are meaningful which leads to the
development of an inflexible way of responding to thoughts.
A more flexible response style can help to alleviate perseveration.
Similarly, the S-REF model specifies that threat monitoring (e.g.,
scanning for symptoms or for negative thoughts) is determined
by positive metacognitive beliefs. More specifically, a person
comes to believe that scanning the environment or one’s mind
and/or body for symptoms will reduce distress whereas it
leads to the persistence of threat and distress. Furthermore,
negative metacognitive beliefs about the uncontrollability and
danger of worry sustain and increase worry. Modifying negative
metacognitive beliefs is fundamentally important in the S-REF
model because, if patients believe that worry is uncontrollable,
they will not attempt to control it. Therefore, it is possible that
through targeting metacognitive beliefs and processes rather than
cognitive content, MCT offers a particularly close “fit” with the
needs of cancer survivors indicating potential for greater efficacy
(McNicol et al., 2013).
The development of MCT for psychological morbidity in
cancer is evolving with encouraging evidence for the explanatory
and therapeutic utility of MCT. There is increasing evidence
for the role of metacognitive beliefs and processes in emotional
distress in cancer survivors from cross-sectional and prospective
studies (Thewes et al., 2013; Cook et al., 2014, 2015a,b; Butow
et al., 2015; Fisher et al., 2018) and in adult cancer patients
undergoing chemotherapy (Quattropani et al., 2016, 2017). There
have been two tests of the potential efficacy of MCT in cancer
survivor. First, an open trial of MCT for emotional distress in
adolescent and young adult cancer survivors found clinically
significant reductions in anxiety, depression and posttraumatic
stress symptoms (Fisher et al., 2015). Second, a multiple baseline
study of MCT in four adult cancer survivors (Fisher et al., 2017)
reported substantial reduction in anxiety, depression and FCR
over six one-hour sessions These studies illustrate that MCT
can rapidly alleviate psychological morbidity in cancer patients
but before progressing to a randomized controlled trial, further
evidence of the potential efficacy and feasibility of delivering
MCT is required. The present study therefore examined if
MCT delivered over six one-hour individual treatment sessions
would result in clinically significant improvements in anxiety,
depression, posttraumatic stress symptoms, fear and cancer
recurrence and overall quality of life immediately following
treatment and over a 6-month follow-up period. The study also
examined if MCT would be associated with reductions in the
metacognitive beliefs and processes.
MATERIALS AND METHODS
Design
An open trial with follow-up at 3 and 6 months evaluated
the potential efficacy of brief MCT for adult survivors of
cancer experiencing emotional distress. Data was also gathered
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on recruitment and retention rates. All participants gave
written informed consent in accordance with the Declaration of
Helsinki. Ethical approval was provided by the National Health
Service North West Research Ethics Committee (reference
15/NW/0820).
Participants and Procedure
Potentially suitable participants were identified from consecutive
referrals to an adult clinical heath psychology service which
specializes in psychological interventions for cancer patients.
Those patients with elevated scores on the Hospital Anxiety
and Depression Scale (HADS; Zigmond and Snaith, 1983)
and indicated a willingness to be approached for possible
participation in an intervention were provided with an
information sheet about the study. Those patients were contacted
and invited to attend an assessment appointment to determine
their suitability for inclusion. Following the informed consent
procedure, clinical and demographic data was obtained by
interview and participants completed a range of questionnaires
assessing the severity of psychological morbidity (see section
on measures). Participants also completed all questionnaires at
post-treatment, and again at 3- and 6-month follow-up. All
questionnaires were returned to an independent assessor who
scored and entered the data.
Twenty seven cancer survivors participated in the study and
met the following inclusion criteria: (i) a score of > 15 on the
Hospital Anxiety and Depression Scale-Total (HADS-T); (ii) had
been diagnosed with cancer ≥ 6 months previously; (iii) were
aged 18 years or over; (iv) had completed acute medical treatment
for cancer (i.e., chemotherapy, radiotherapy, surgery); (v) were
not receiving concurrent psychological treatment; (vi) were not
actively suicidal; (vii) reported no current substance use; (vii)
were not experiencing a psychotic or organic illness; (viii) were
free from psychotropic medication or has been on a stable dose
for at least 8 weeks; and (ix) were able to speak and understand
English.
Intervention
Metacognitive therapy was delivered over a maximum of 6
individual face-to face sessions that were 45–60 min in duration.
The intervention followed a manualized protocol (Wells, 2009).
As the intervention was transdiagnostic, MCT followed the same
protocol for each patient in the study regardless of symptom
presentation. In session 1, the formulation template used when
treating depression served as the basis for the development
of an idiosyncratic case formulation for each participant, thus
following the approach adopted in previous evaluations of
MCT for cancer survivors (McNicol et al., 2013; Fisher et al.,
2015, 2017). The next step in treatment is socialization which
proceeds by sharing the case formulation and by Socratic
Questioning to help the patient understand that each aspect
of the CAS and several types of metacognitive beliefs are
maintaining emotional distress. MCT then focuses on modifying
negative beliefs about uncontrollability of rumination/worry
through training in detached mindfulness (DM) and in
rumination/worry postponement (Wells, 2009). Patients are
helped to understand how naturally occurring thoughts (e.g.,
“I’m useless,” “What if my cancer comes back?,” “My family will
not be able to cope”) do not necessarily lead to perseveration.).
Rumination/worry postponement is a behavioral experiment to
challenge the negative metacognitive belief that perseveration is
an uncontrollable process. Positive metacognitive beliefs about
the helpful nature of worry/rumination and the other unhelpful
coping responses are also highlighted to the patients and
addressed. Final sessions address relapse prevention and involve
modifying remaining use of the “cognitive attentional syndrome,”
reviewing any remaining conviction in positive and negative
metacognitive beliefs and consolidating and alternative ways of
responding to negative thoughts. Three therapists delivered MCT
(PF, AB, and LF). Supervision was provided by PF on a weekly
basis.
Measures
Hospital Anxiety Depression Scale (HADS; Zigmond
and Snaith, 1983)
The HADS is a 14-item self-report questionnaire measuring
anxiety and depression (seven items each) over the past week.
Each item is rated on a 4-point scale (0–3). Scores for each
subscale range from 0 to 21 with higher scores reflecting more
sever anxiety or depression. Scores of 11 or more on each of
the subscales indicate caseness. Combining the two subscales
provides a measure of emotional distress. The HADS-Total is the
“gold standard” outcome measure for evaluating the efficacy of
interventions on emotional distress in cancer populations, and
has excellent psychometric properties (Luckett et al., 2010).
Impact of Events Scale-Revised (IES-R; Weiss, 2007)
The IES-R is a 22-item self-report questionnaire measuring
trauma-related symptoms The total scale score ranges from 0
to −88 with higher scores indicative of more severe trauma
symptoms. A total score of ≥ 33 indicates a probable diagnosis
of PTSD (Weiss, 2007). The IES-R is validated for use in cancer
populations with good psychometric properties (Salsman et al.,
2015).
Fear of Cancer Recurrence Inventory (FCRI; Simard
and Savard, 2009)
The FCRI is 42-item self-report questionnaire assessing 7 aspects
of FCR. Each item is rated on a 5-point scale (0–4). A total score
for the FCRI is obtained by summing scores on the 7 subscales,
with higher scores indicating greater severity (range 0–168). The
FCRI is the most validated measure of FCR across a wide range
of cancer types (Simard and Savard, 2009).
Functional Assessment of Cancer Therapy-General
(FACT-G; Cella et al., 1993)
The FACT-G is a 27 item self-report questionnaire that measures
four domains of health-related quality of life (HRQOL). Each
item is rated on a 5-point scale from 0 (not at all) to 4 (very
much). The FACT-G total score ranges from 0 to 108 with
higher scores indicating a better HRQOL. The FACT-G has been
used extensively in mixed cancer populations and has excellent
psychometric properties (Brucker et al., 2005).
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Metacognitions Questionnaire-30 (MCQ-30; Wells
and Cartwright-Hatton, 2004)
The MCQ-30 measures 5 domains of metacognition by 30 items.
Participants rate the extent to which they “generally agree” with
statements presented on a 4-point scale from 1 (do not agree)
to 4 (agree very much), providing total scores for each subscale
ranging from 6 to24. Higher scores indicate greater conviction in
metacognitive beliefs. The MCQ-30 assesses: (1) positive beliefs
about worry, (2) negative beliefs uncontrollability and danger
of worry, (3) cognitive confidence, (4) beliefs about the need
to control thoughts, and (5) cognitive self-consciousness. The
MCQ-30 has been validated for use in cancer patients (Cook et al.,
2014).
Cognitive Attentional Scale-1 (CAS-1; Wells, 2009)
The CAS-1 is a 10 item self-report questionnaire that assesses
metacognitive processes and beliefs. Items 1 to 6 assess the
fundamental components of the CAS (perseverative thinking,
threat monitoring and unhelpful coping strategies) Each item is
rated on a 10-point scale from 0 (none of the time) to 100 (all
the time). Items 7 to 10 assess metacognitive beliefs and are not
reported in the present study. To provide an overall measure of
the CAS, the 6 items were summed and divided by the number of
items. The same method has been used previously (Fisher et al.,
2016; Heffer-Rahn and Fisher, 2018).
Statistical Analyses
Intention to treat (ITT) analyses were used to determine
the potential efficacy of brief MCT for emotional distress
in cancer survivors. Missing data for the non-completers in
the study were replaced by using the last observation carried
forward (LOCF) method. The LOCF has been considered a
conservative approach when evaluating treatment outcomes
in open trials. Treatment effects across time (pre-treatment,
post-treatment, and 3- and 6-month follow-up) were assessed
with repeated-measures analysis of variance (ANOVA);
the Greenhouse–Geisser correction was applied when the
assumption of sphericity was violated. Main effects were
followed by Bonferroni-adjusted pairwise comparisons for each
outcome measure. Within group effect sizes were calculated
using Cohen’s d to assess the magnitude of treatment effects
from pretreatment to post-treatment and from pre-treatment
to both 3- and 6-month follow-ups. To determine the clinical
significance of treatment effects the methodology developed
by Jacobson et al. (1984) and Jacobson and Truax (1991) was
applied to the HADS-Total. Each patient can be allocated to one
of four treatment outcomes: reliable deterioration, no change,
reliable improvement, or recovered. The first three outcomes are
calculated using from the Reliable Change Index (RCI), which
determines whether the magnitude of change is statistically
significant. Data to calculate the RCI was drawn from a large
non-clinical sample (Crawford et al., 2001). The cut-off score
for the HADS-Total was ≤ 13 determined using “criterion a”
To be classified as recovered, patients must demonstrate reliable
change and their post-treatment or follow-up scores must be
below the cut off score. The data were analyzed using SPSS
version 24.
TABLE 1 | Participant characteristics.
Mean (SD) Range
Age 51.15 (11.67) 29–67
Age at time of cancer diagnosis 46.71 (10.99) 28–64
Months since completion of acute medical treatment 25.81 (27.93) 3–142
N
Gender
Female 23
Male 4
Ethnicity
White Caucasian 26
Asian 1
Cancer Diagnosis
Breast 13
Hematological 6
Ovarian 3
Sarcoma 2
Colorectal 1
Ocular 1
Lung 1
Cancer Treatment
Chemotherapy, radiotherapy, and surgery 8
Chemotherapy plus surgery 5
Chemotherapy alone 4
Surgery alone 3
Chemotherapy, plus radiotherapy 2
Radiotherapy plus surgery 1
Radiotherapy alone 1
Other/not reported 3
Employment Status
Employed 13
Unemployed 14
Education Level
School level or higher No qualifications 26 1
Relationship Status
Married/cohabiting 11
Live alone 16
Psychotropic Medication
Current taking 11
Previously taken 5
Never taken 11
Previous Psychological Treatment
Yes 17
No 10
Distress Outcomes
Anxiety (HADS-A > 11) 26 (96%)
Depression (HADS-D > 11) 12 (44%)
PTSD symptoms (IES-R > 33) 25 (93%)
RESULTS
Participant Characteristics
Forty-three consecutive referrals were identified as
potentially eligible. There were 16 patients who did not
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TABLE 2 | Means, standard deviations (in parentheses) and repeated measures analysis of variance for outcome measures: Intention-to-treat sample (n = 27).
Measure Pre-treatment Post-
treatment
3-month
follow-up
6-month
follow-up
F (df)
HADS -Total 25.04 (5.65) 12.70 (9.61) 13.00 (9.99) 12.67 (10.12) 39.76 (2.15,56.05) p < 0.0001
HADS - Anxiety 14.44 (3.51) 7.85 (5.14) 7.96 (5.49) 7.52 (5.44) 32.85 (2.21,57.30) p < 0.0001
HADS - Depression 10.74 (3.77) 4.81 (4.79) 5.04 (4.89) 5.15 (5.23) 31.60 (2.03,52.71) p < 0.0001
IES-R -Total 53.15 (16.43) 26.04 (26.93) 27.92 (26.64) 27.81 (25.35) 26.56 (2.32,60.28) p < 0.0001
FCRI- Total 108.29 (22.18) 59.59 (38.84) 63.37 (36.63) 63.81 (36.73) 34.42 (1.49,38.48) p < 0.0001
FACT-G-Total 54.33 (14.94) 76.87 (20.16) 74.55 (21.63) 74.94 (22.73) 31.09 (2.21,57.43) p < 0.0001
MCQ-30 Positive beliefs 11.74 (4.66) 8.22 (3.73) 8.29 (3.61) 8.33 (3.89) 9.47 (1.48,38.53) p < 0.001
MCQ-30 Negative beliefs 18.59 (3.27) 11.85 (5.23) 12.03 (5.21) 11.70 (5.04) 28.87 (1.78,46.28) p < 0.0001
MCQ-30 Cognitive confidence 15.74 (5.28) 11.41 (4.98) 12.48 (5.61) 11.77 (5.58) 13.35 (2.18,55.06) p < 0.0001
MCQ-30 Need for control 14.41 (4.38) 10.07 (4.73) 9.33 (4.72) 9.26 (4.77) 23.30 (1.40,36.40) p < 0.0001
MCQ-30 Cognitive self-consciousness 17.93 (3.98) 12.66 (6.09) 12.52 (4.87) 12.59 (5.15) 23.85 (2.27,59.05) p < 0.0001
CAS-1 55.25 (19.19) 20.06 (25.85) 20.86 (26.19) 24.32 (28.61 44.67 (2.18,56.69) p < 0.0001
df, degrees of freedom; HADS, Hospital Anxiety and Depression Scale; IES-R, Impact of Event Scale-Revised; FCRI, Fear of Cancer Recurrence Inventory; FACT-G,
Functional Assessment of Cancer Therapy-General; MCQ-30, Metacognitions Questionnaire-30; CAS-1, Cognitive Attentional Scale.
TABLE 3 | Within group effect sizes (Cohen’s d) for outcome measures at
post-treatment and 3- and 6-month follow-up.
Post-
treatment
3-month
follow-up
6-month
follow-up
HADS-Total 1.56 1.48 1.51
HADS-Anxiety 1.49 1.41 1.51
HADS-Depression 1.37 1.31 1.23
IES-R Total 1.21 1.14 1.18
FCRI-Total 1.66 1.48 1.46
FACT-G-Total –1.27 –1.09 –1.07
MCQ-30 Positive beliefs 0.83 0.83 0.79
MCQ-30 Negative beliefs 1.51 1.50 1.62
MCQ-30 Cognitive confidence 0.84 0.59 0.75
MCQ-30-Need for control 0.95 1.12 1.12
MCQ-30-Congnitive self-consciousness 1.02 1.22 1.16
CAS-1 1.55 1.49 1.27
HADS, Hospital Anxiety and Depression Scale; IES-R, Impact of Event
Scale-Revised; FCRI, Fear of Cancer Recurrence Inventory; FACT-G,
Functional Assessment of Cancer Therapy-General; MCQ-30, Metacognitions
Questionnaire-30; CAS-1, Cognitive Attentional Scale.
enter the study; 10 did not wish to participate, 3 did
not attend the assessment interview 1 patient did not
have a have a cancer diagnosis, 1 patient did not meet
the threshold for severity of distress with a HADS-T
score of less than 16 and 1 patient had a recurrence of
cancer.
Twenty-seven patients began the trial of whom 20 completed
treatment; a completion rate of 74%. Of the seven patients who
did not complete the six sessions of MCT; three patients attended
only one session, two patients 2 sessions, one patient 3 sessions
and the final patient attended 4 sessions but sporadically and
decided that it was not feasible to continue therapy. Reasons
for non-completion were; one patient was hospitalized for
cancer recurrence, one participant stopped therapy to be able
to provide full time care for a relative, 2 participants did not
wish to undertake psychological therapy and 3 patients dropped
out without providing a reason. The demographic and clinical
characteristics of the sample shown in Table 1. It is notable
that 96% of the sample met caseness for anxiety with 93% also
scoring above the clinical cut-off for PTSD. Additionally, 8 of the
27 patients had experienced a cancer recurrence, none of these
patients discontinued MCT.
Treatment Effects
There were significant main effects of time on all outcome
measures (Table 2). Follow-up Bonferroni pairwise comparisons
demonstrated significant differences from pre-treatment to
post-treatment, and from pre-treatment to 3-and 6-month follow
up on all outcome measures indicating that treatment effects
were maintained. Overall, there was significant improvement
TABLE 4 | Clinical significance outcomes on HADS-total.
Post-treatment 3-month follow-up 6-month follow-up
No change Improved Recovered Deteriorated No change Improved Recovered No change Improved Recovered
ITT 5 5 17 1 4 8 14 7 5 15
(n = 27) 19% 19% 62% 5% 25% 17% 58% 26% 19% 56%
Completers 1 3 16 1 0 6 13 3 3 14
(n = 20) 20% 0% 80% 5% 0% 30% 65% 15% 15% 70%
ITT: intention to treat sample; Completers: treatment completers sample.
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across all symptom and quality of life measures and significant
reductions in metacognitive beliefs (MCQ-30) and processes
(CAS-1).
Effect Size Estimates
Within group effect sizes for the ITT sample are shown
in Table 3. There are large pre to post-treatment effect
sizes across all outcome measures (0.83–1.66). There are
comparable effect sizes across all measures at both follow-up
timepoints illustrating that the magnitude of treatment
effects is maintained from post-treatment to 6-month
follow-up.
Clinically Significance of Treatment
In the ITT sample, most participants were recovered on the
HADS-Total at post-treatment and across the follow-up period.
In terms of the proportion of patients that responded to
treatment, 81% were improved at post-treatment and 74% at
6-month follow-up. Examination of the recovery rates for those
patients that completed treatment shows recovery rates of 80%
at post-treatment and 70% at 6-month follow-up. A summary
of the clinical significance of treatment outcomes is shown in
Table 4.
DISCUSSION
This study provides further support for the potential of
brief MCT to alleviate psychological morbidity in cancer
survivors. Following six 1-hour sessions of MCT, there were
significant reductions in anxiety depression, post-traumatic stress
symptoms, FCR and improvements in quality of life. There
were also significant reductions in metacognitive beliefs and
the CAS as predicted by the metacognitive model (Wells and
Matthews, 1994, 1996). Treatment gains were sustained across
all measures of psychological morbidity and metacognitive
beliefs and processes through to 6-month follow-up. The
practical significance as opposed to the statistical significance
of the results was assessed using the Jacobson approach
to clinical significance. In those patients who completed
brief MCT, there were very high recovery rates on the
primary outcome variable assessing the severity of general
distress; 80% of patients were recovered following six one-hour
sessions of individually delivered MCT. The recovery rate of
70% at 6-month follow-up suggests that the effects of the
intervention persist beyond treatment completion. Brief MCT
appeared acceptable to cancer survivors with approximately
75% of participants starting treatment completed treatment.
It is possible that the treatment completion rate can be
improved and early drop-outs from treatment prevented by
ensuring patients are more effectively socialized to the aims
of MCT.
The within group effect sizes on FCR provide the opportunity
to benchmark the effects of brief MCT with those reported
in recent randomized controlled trial evaluating an integrative
approach for FCR. The psychological treatment in the trials
conducted by Butow et al. (2017) evaluated an intervention
(ConquerFear) based on the treatment components drawn from
three theoretical frameworks; common sense model (Leventhal
et al., 1992) the self-regulatory model (Wells and Matthews, 1994)
and relational frame theory (Hayes et al., 2006). Although the
ConquerFear intervention was more efficacious than an attention
control condition, the within group effect size for FCR from pre
to post-treatment was 0.77. This compares to a within group
effect size of 1.66 in the present study. Although, the present
study had a much smaller sample size thereby limiting the
generalizability of this finding. However, unlike the ConquerFear
study, our open trial included participants with depression
and severe trauma symptoms indicative of PTSD. Developing
specific interventions for each aspect of psychological morbidity
for cancer survivors may be unnecessary and integrating
treatment components from theoretically inconsistent models
could “dilute” treatment efficacy and compromise therapist
training (Wells and Fisher, 2015; Byrne et al., 2018).
The present open trial is a valuable step in the translation
of MCT from adult mental health populations to cancer
survivors and is following the recommended framework for
translating psychological interventions to a new population
(Craig et al., 2008). The limitations of open trials are well
known but should not undermine their place in treatment
development research (Craig et al., 2008). No data was collected
on either treatment adherence or therapist competency beyond
that achievable through weekly supervisory sessions. Subsequent
studies should include independent assessment of both treatment
adherence and therapist competency to increase confidence in
the conclusions drawn and that any treatment effects were
attributable to MCT.
A comparatively small sample was used, but the sample
appeared representative of cancer survivors referred to the
clinical health psychology service. Other limitations include the
lack of ethnic diversity and that most of the sample were female,
thereby compromising external validity. Treatment outcome was
assessed exclusively by self-report questionnaires in the present
study. Although exclusive reliance on self-report questionnaires
could be considered a methodological weakness, the study
was not focused on changes psychiatric diagnosis, rather the
study was designed to measure general distress for which the
“gold standard” outcome measure for evaluating the efficacy of
interventions on emotional distress in cancer was used (Luckett
et al., 2010).
Overcoming other limitations of open trials can be achieved
through conducting randomized controlled evaluation. It would
be valuable to assess the hypothesized mechanisms of change
in the context of an RCT against the current recommended
treatment approaches, it may be that the treated patients who
recover change to most on metacognitive variables regardless
of the treatment received. There were statistically significant
reductions in all metacognitive beliefs and the CAS over
treatment, which were maintained through to the 6-month
follow up assessment. This study adds to the extant literature
that MCT has the potential to be an efficacious psychological
intervention for adult cancer survivors. Given the limited
outcomes of currently available interventions, there is an obvious
need to conduct a controlled evaluation of the potential of
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brief MCT to alleviate psychological morbidity in cancer
survivors.
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